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What is already known on this topic?  
• Depression and anxiety have been shown to affect patients with psoriasis 
What does this study add? 
• Routine use of screening questionnaires will identify new, clinically significant 
depression and anxiety in people with psoriasis.  
• Risk factors for major depressive disorder and / or generalised anxiety disorder in 
people with psoriasis include female sex, psoriatic arthritis, psoriasis severity and 
prior psychiatric morbidity. 
• The quality of life screening tool in routine use misses important psychiatric 
morbidity.  
 
ABSTRACT 
Background: National Institute for Health and Care Excellence (NICE) guidance 
recommends assessment of psychological and social well-being in people with psoriasis.   
Objectives: To systematically screen for depression and anxiety in patients with psoriasis in 
routine clinical practice and identify at-risk groups for psychiatric morbidity.  
Methods: Consecutive patients attending a single, tertiary centre over a 10-month period 
were invited to complete Patient Health Questionnaire Depression Scale (PHQ-9), 
Generalized Anxiety Disorder Scale (GAD-7) and Dermatology Life Quality Index (DLQI) as 
part of the IMPARTS: Integrating Mental and Physical healthcare; Research, Training and 
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Services. Information on demographics, treatment and clinical disease severity were collated 
from EPR. Regression models were used to identify at-risk groups for psychiatric morbidity. 
   Results: Of 607 patients (56.2% on biologics) included, 9.9% (95%CI: 7.5-12.3%) 
screened positive for major depressive disorder and 13.1% (95%CI: 10.4-15.8%) for 
generalised anxiety disorder ([GAD] GAD-7 >9). Suicidal ideation was reported in 35% of 
MDD; DLQI was <10 in 38.3% and 45.6% cases of MDD and GAD respectively.   After 
adjusting for covariates, risk of MDD or GAD was significantly increased in women, those 
with severe clinical disease, psoriatic arthritis and previous depression/anxiety; risk of GAD 
was significantly increased with Asian ethnicity and use of topical treatments only.  
   Conclusions: Systematic screening for anxiety and depression identifies clinically 
important levels of depression and anxiety that may be missed using DLQI alone. Women, 
those with severe disease, psoriatic arthritis and/or a prior history of psychiatric morbidity 
may be at particular risk. 
 
1. INTRODUCTION 
Psoriasis is a chronic inflammatory skin condition affecting 1-3% of the population. Even 
when not clinically severe, psoriasis can adversely impact on psychological and social 
wellbeing, demonstrating a complex relationship between psychological and dermatological 
health.1 People with psoriasis may have difficulty coping with their appearance and feel 
stigmatised, which in turn can lead to overt clinical depression and/or anxiety.2 Whilst 
important in their own right, anxiety and depression may also prevent effective treatment.3  
Guidelines on management of long-term conditions, and specifically psoriasis,4 recommend 
direct enquiry about the impact of psoriasis on well-being yet  few clinicians work in this way 
as the acceptability and time taken for such holistic assessment may be problematic.5 
 
The IMPARTS (Integrating Mental and Physical Healthcare: Research Training and 
Services) programme aims to address this by providing a multifaceted platform of clinical 
and research services to integrate mental healthcare into routine care.  Patients’ health 
needs are identified via patient-completed questionnaires on an e-tablet and results 
automatically populate the electronic patient record (EPR). In parallel the programme trains 
staff in basic mental health skills, identifies care pathways for individuals with mental health 
needs, and develops disease specific self-help materials. The programme has been 
implemented in 25 clinical services across two NHS Foundation Trusts in South London and 
has been shown to be acceptable to patients and staff.6  
 
 
A
cc
ep
te
d 
A
rt
ic
le
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
IMPARTS programme was introduced in our tertiary psoriasis service to systematically 
assess for psychiatric morbidity as part of a planned, specialty wide roll out.  Using data 
made available via the programme we aimed to (i) estimate the prevalence of psychiatric 
disorders (depression and anxiety) in our patient cohort and (ii) to identify any baseline 
demographic and /or clinical characteristics (including disease severity, psoriatic arthritis, 
prior psychiatric morbidity) that are associated with depression and/or anxiety. Identification 
of at risk groups may be of value to clinicians in settings with limited resources and/or 
prompt earlier referral. 
 
2. METHODS 
This is a cross-sectional, single centre study in a tertiary psoriasis service. As the IMPARTS 
programme is a clinical innovation used in routine care, patients were not formally consented 
to participate, but were informed that data might be used for research purposes and could 
opt out. This complies with the basis of the IMPARTS programme ethical approval 
(IMPARTS Research Database REC reference: 12/SC/0422).  All applications to use data 
collected routinely under the IMPARTS programme are scrutinised by a patient-led oversight 
committee to ensure that the use of data is appropriate and in line with ethics committee 
approval.  
 
2.1 Patients: All patients (new and return) with a clinical diagnosis of psoriasis were invited 
to complete self-report questionnaires using a touch-screen tablet device with Wi-Fi 
connectivity to the hospital EPR.  A health-care assistant or registered nurse (trained in use 
of the tablet device) explained the process, and issued an information leaflet detailing the 
reasons for collecting data. An opt-out consent process was followed; those who chose not 
to participate were invited to participate on subsequent attendances.  
 
2.2 Procedure: Self-report questionnaires Patient Health Questionnaire (PHQ),7 
Generalised Anxiety Disorder (GAD)8 and Dermatology Life Quality Index (DLQI)9 were 
completed on the electronic tablet. The PHQ-9 has been shown to be a reliable and valid 
measure of depression severity in primary care7 and physically ill populations in secondary 
care.10-12 The GAD-7 is a reliable and valid measure of anxiety in primary care,8 the general 
population13 and secondary care.14 The DLQI is widely used in dermatology for research 
purposes and has adequate validity and reliability.9 Each patient completed PHQ-215 and 
GAD-216 consisting of the first two items of the PHQ-9 and GAD-7, respectively. Patients 
answering positively (“more than half the days” or “nearly every day”) to at least one item 
went on to complete remaining items of the corresponding measure.  Completed data from 
PHQ-9, GAD-7 and DLQI questionnaires automatically populated the EPR and was 
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assigned depression and anxiety severity categories (see Table 1) alongside corresponding 
referral advice. Using a stepped care approach, pathways of referral were developed with 
the IMPARTS programme and included: alert general practitioner (GP) and advise referral to 
local primary care psychology team (Improving Access to Psychological Therapies; IAPT); 
review by dedicated psoriasis clinic psychologist; and liaison psychiatry review.17, 18 Referral 
to the psoriasis service clinical psychologist (present during clinic) was recommended where 
a complex interaction between dermatological condition and emotional health was identified. 
Identification of suicidal ideation or MDD with severe symptoms generated referral advice for 
non-urgent liaison psychiatry review. An urgent referral was advised for those screening 
positive for both. The expectation was that the reviewing clinician would discuss positive 
findings with the patient and the requirement for onward referral. 
Data from patients who attended clinic more than once during the study period were 
included only once (first recording) although participation occurs serially at each subsequent 
attendance. Incomplete questionnaires (1 or more questions) were excluded. 
 
2.3 Demographic and clinical information were extracted from EPR and included baseline 
demographics (age, sex, and ethnicity), history of psoriatic arthritis (diagnosed by a 
rheumatologist); past or on-going depression (defined as at least one of the following: 
diagnosis of depression in a clinic letter during the preceding year, treatment with 
antidepressant medication, e.g. selective serotonin reuptake inhibitors or tricyclic 
antidepressant, listed in the clinic letter during the preceding year and/or a GP letter from the 
last 5 years with a diagnostic coding for depression); past or on-going anxiety (defined as a 
diagnosis of anxiety or obsessive compulsive disorder listed in a clinic letter in the last year 
and/or a GP letter from the last 5 years with a diagnostic coding for anxiety); psoriasis 
phenotype; current treatment for psoriasis (none, topical only, phototherapy [UVB and bath 
PUVA], standard systemic [any of ciclosporin, methotrexate, fumaric acid esters, acitretin, 
systemic PUVA]) or therapy with a biologic agent (any of etanercept, adalimumab, 
ustekinemab or infliximab). If a patient was receiving biologic and standard systemic therapy 
they were placed in the biologic therapy category. Similarly, if a patient was taking systemic 
therapy and undergoing phototherapy they were placed in the systemic category. Disease 
severity was recorded from a PASI score taken within one month before/after PHQ-9, GAD-
7 and DLQI questionnaire completion. 
 
2.4 Statistical analysis 
Statistical analysis was performed using STATA v.10. The prevalence of MDD and GAD is 
expressed as the percentage of cases determined by PHQ-9 and GAD-7 variables, 
respectively. Multiple logistic regression models were then created to examine the 
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relationships between disease severity, age, gender, ethnicity, treatment type, presence of 
Psoriatic Arthritis (PsA) and a historic psychiatric diagnosis and the presence of psychiatric 
disorder (GAD and MDD), providing odds ratios (OR), 95% confidence intervals (95%CI) 
and p-values.  
 
3. RESULTS 
3.1 Patients 
636 patients completed screening for the first time during the study period 13/6/13-24/4/14. 
Out of 636, 607 had a diagnosis of psoriasis thus were eligible for inclusion (5.1% [31/607] 
newly referred patients, 95.0% [576/607] return patients). We evaluated take up of screening 
in the first 165 patients and found 1.8% (3/165) were not screened for the following reasons: 
patient declined, insufficient time, and IT problems.6 
 
3.2 Descriptive data 
Patient demographics are shown in Table 2. The majority of patients were male (65.4%), 
White British (69.5%), with chronic plaque psoriasis (95.7%). In total, 56.2% of patients were 
receiving biologics. A previous history of depression and anxiety was noted in 8.1% and 
2.3% of patients respectively. The mean PASI and DLQI scores were 5.5 (SD= 5.7, range 0-
50) and 3.6 (SD= 7.1, range 0-30) respectively.  
 
3.3 Prevalence and severity of psychiatric disorder identified by screening 
Sixty patients (9.9%, 95%CI: 7.5-12.3%) screened positive for probable major depressive 
disorder (MDD), see Figure 1a. Of these, 41.7% (95%CI: 28.9-54.5%) reported severe 
symptoms of MDD, see Figure 1b. A total of 3.5% (95%CI: 2.0-4.9%) indicated the presence 
of suicidal ideation 4.8% of whom were new patients.  68.3% of those identified cases of 
MDD had no recorded history of depression (see Table 3) and 23 (38.3%) patients with 
MDD had DLQI scores <10. Seventy-nine (13.1%, 95%CI: 10.4-15.8%) patients had 
probable generalised anxiety disorder (GAD) (see Table 3). 69.6% of those identified cases 
of GAD had no recorded history of anxiety (see Table 3).  Additionally, 36 (45.6%) patients 
with GAD had DLQI scores <10.  
In total, 8.1% (95%CI: 5.9%-10.2%) of patients had both MDD and GAD, and 14.8% 
(95%CI: 12.0%-17.7%) had MDD or GAD (see Figure 1a). Of note 35% of this group with 
both psychiatric disorders had a DLQI of less than 10 including 2 patients with DLQI of 0 
despite screening positive for both GAD and MDD. 
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19.4% (6/31) of new patients screened positive for MDD (66.6% of whom had severe MDD) 
compared with 9.1% (55/607) of return patients. Eight new patients (8/31, 25.8%) screened 
positive for GAD compared with 71 (71/576, 12.3%) of return patients (patient/treatment 
variables not controlled for between new/return groups). 
 
3.4 Referral pathway advice 
For anxiety, the threshold for clinical psychologist review was reached in 78.3% (47/60) of 
patients and 34.0% (16/47) of these patients took up the offer to see the clinical 
psychologist. In the remainder, signposting advice to alert the GP and advise referral to 
IAPT was given, although uptake of this advice was not recorded. 
For depression, the threshold for urgent referral to liaison psychiatry was reached in 25% 
(15/60) of patients and clinical psychologist review was suggested in 35% (21/60), 23.8% 
(5/21) of whom wished to see the psychologist when offered. In the remainder, non-urgent 
referral to liaison psychiatry or alert GP and advise referral to IAPT was suggested (uptake 
not recorded). 
 
3.5 Risk factors identified for Psychiatric Disorder 
(i) Anxiety 
Risk of GAD was significantly increased in females (OR 1.88, p=0.04), Asian patients (OR 
3.42, p=0.001), those with co-existent PsA (OR 1.92, p=0.003), severe psoriasis (OR 1.07, 
p=0.007) and those with a history of anxiety (OR 8.70, p<0.001). In comparison to patients 
receiving biologic therapy, patients using topical treatments only had three times the odds of 
having GAD (OR 3.66, p=0.001). There were no significant relationships between age or 
psoriasis phenotype and presence of GAD (see Table 3). 
 
(ii) Depression 
Female patients (OR 2.07, p=0.03), patients with PsA (OR 2.11, p=0.003) and those with 
previous depression (OR 6.86, p<0.001) were at increased risk of screening positive for 
MDD. Patients with more severe psoriasis had increased odds of MDD (OR 1.10, p<0.001) 
than those with less severe disease. There were no significant relationships between age, 
ethnicity, psoriasis phenotype or treatment modality and presence of MDD (see Table 3).  
It is known that a proportion of Dermatology patients are at increased risk of suicide and 
screening has been suggested since early detection can minimise risk of suicide.19 In the 
group with MDD, 35.0% (3.5% of total cohort) had suicidal ideation and 20.0% of this group 
were known to have a previous diagnosis of depression. The proportion of patients receiving 
the various different treatment modalities was similar to the total cohort. 
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4. DISCUSSION  
We demonstrate that women, those with severe clinical disease, psoriatic arthritis and/or a 
prior history of psychiatric morbidity may be at particular risk of anxiety and/or depression. 
Additionally, DLQI as a means to assess impact of disease misses clinically important 
psychiatric disorders. Strengths of our study include high uptake and the use of validated 
tools to detect depression and anxiety.  
 
4.1 Prevalence  
Rates of depression in psoriasis are known to be high.20,21 We were surprised that the 
prevalence of probable depression in our cohort (9.9%), from a tertiary centre and thus a 
likely “high-need” cohort, was lower than other tertiary centres.22 We also found the 
prevalence of anxiety (13.1%) to be lower than previous authors in a tertiary psoriasis clinic 
(43%).2 In line with others, we found anxiety to be more prevalent than depression in our 
cohort.2 In keeping with the lower prevalence of depression in our cohort, active suicidal 
ideation (3.5%), was approximately half that in similar patient groups (5.5%).23 
 
Reasons for lower prevalence of psychiatric disorders in this study compared with others 
may be due to the likely high uptake in our group (1.8% only not screened in the first 165 
patients) thus reducing volunteer bias with a near complete cohort of patients. Additionally, 
use of more stringent screening tools may have contributed. PHQ-9 more closely follows the 
4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
classification of psychiatric disorders compared with, for example, the Hospital Anxiety and 
Depression Scale,24 used by other authors,2 making direct comparison difficult. The GAD-7 
questionnaire was also developed based on DSM-IV criteria for generalised anxiety 
disorder.8  
 
It is notable that previous studies looking at psoriasis and psychiatric disorders used data 
from 1987-2002 and included no patients treated with biologic agents.25 Since 2002, biologic 
agents are more widely used with the majority of patients in our cohort receiving biologic 
therapy (56.2%).  
 
Another interesting finding in our cohort was the detection of both high numbers of probable 
“new” or previously “undetected” diagnoses of MDD/GAD in patients not already known to 
have psychiatric co-morbidity (71.3% and 8.6% respectively). Furthermore, in patients with 
DLQI less than 10 (suggestive of no to moderate effect of skin disease on quality of life), 
38.3% and 45.6% cases had MDD and GAD respectively, suggesting that 1 in 3 cases of 
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MDD and GAD would be missed without additional screening tools. Thus our data 
demonstrate the use of DLQI alone to assess impact of disease is insufficient. 
 
4.2 Risk Factors for Depression / Anxiety in Psoriasis 
We found the risk of GAD and MDD was increased in females, those with co-existent PsA, 
severe psoriasis and those with a previous history of anxiety or depression respectively. 
GAD was also increased in patients using topical treatments only compared to biologic 
therapy. Similarly, Asian ethnicity was associated with increased risk for GAD in this cohort 
compared to White British patients after controlling for disease severity.  
With respect to ethnicity, we are not aware of quantitative data in psoriasis patients looking 
at this as a risk factor for psychiatric morbidity. However, PHQ-9 and GAD-7 questionnaires 
have not been extensively evaluated in different racial/ethnic populations.26 Sex as a risk 
factor for psychiatric morbidity in psoriasis has been explored before with mixed results.2,21  
In both depression and anxiety we noted those with psoriatic arthritis to be at high risk. 
Perhaps, in part, these findings can be explained by the association of depression with 
increasing co-morbidities.27 Additionally symptom overlap may exist between depressive 
symptoms and those related to living with psoriatic arthritis, for example pain affecting loss 
of desire to go out rather than mood per se.28 Nevertheless, our data highlight that psoriasis 
patients with arthritis are a population particularly vulnerable to adjustment difficulties.  
The finding that previous psychiatric morbidity further increased risk of GAD/MDD may 
reflect continued difficulties in coping with psoriasis in the absence of psychological 
intervention or reflect the same depressive episode and notwithstanding, a depressive 
episode increases risk of depressive relapse.29 Unsurprisingly, MDD/GAD appeared to be 
higher in patients attending for the first time than return patients to this tertiary clinic. 
 
4.3 Limitations 
These data are collected from a single, high need, tertiary centre and thus may not be 
generalisable. Additionally as these data are extrapolated from screening tools, all 
discussions are based on probable diagnoses of anxiety or depression rather than equating 
to actual diagnosis of these psychiatric disorders. However PHQ-9 has been shown to have 
a sensitivity of 78% and specificity of 91% for major depression30 in secondary care. The 
GAD-7 questionnaire (at a cut off score of 5) has been shown to have a sensitivity of 78.1% 
and specificity of 74.6% in secondary care.14 Our inability to control for co-morbidities e.g. 
history of cancer, ischaemic heart disease, and obesity may also have affected our results.31 
It should also be noted that these screening tools are unable to determine causation: 
depression and anxiety could be a direct consequence of skin disease or in fact coincident 
A
cc
ep
te
d 
A
rt
ic
le
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
findings. It is likely an understanding of this would affect onward pathway for treatment of 
these co-morbidities and thus should perhaps be a focus of future research. 
Although uptake data of suggested strategies to deal with identified psychiatric morbidity 
was missing in this study, it would be interesting to address this and examine effects on 
health outcomes.  
 
An additional consideration is the statistical power of these analyses. Although our overall 
sample size of 607 makes this one of the largest studies of its kind in dermatology, the small 
table cell sizes for patients with MDD and GAD make power low for some variables. A 
retrospective power calculation indicates that for depression we had a prevalence of 9.9% 
and a sample size of 607. This would allow us to detect a difference in proportions of 20% 
versus 40% with 83% power and 95% confidence. For anxiety, a prevalence of 13.1% and a 
sample size of 607 enables us to detect a difference in proportions of 20% versus 40% with 
81% power and 95% confidence. 
 
CONCULSIONS 
These data suggest that the burden of depression and anxiety in tertiary psoriasis 
populations is significant. Psychological support and a multidisciplinary approach in psoriasis 
patients may be indicated for adjustment difficulties of mood and anxiety in line with current 
NICE guidance in promoting an holistic approach to care and improving quality of life.4, 18 
Some patient groups may be at greater risk of MDD and/or GAD due to other medical or 
social factors, and quality of life screening tools in routine use do not reflect psychiatric 
morbidity. Additionally, through improved detection, this evidence may support a business 
case for increased access to psychological services in specialist departments. 
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Table 1: Depression and anxiety categories and severity using PHQ and GAD 
questionnaires. 
 
Depression  Categories Criteria
PHQ-9 
questionnaire* 
Probable Major Depressive 
Disorder (MDD) 
Patients answering positively to at least 1 
PHQ-2 item AND to 4 or more of the 
remaining 7 PHQ-9 items. 
 
(Severity of MDD:  
Severe MDD: PHQ-9 20-27 
Moderate MDD: PHQ-9 15-19 
Mild MDD: PHQ-9 9-14) 
 
 Some Symptoms of 
Depression 
Patients answering positively to at least 1 
PHQ-2 item
 No symptoms of 
Depression 
Patients answering positively to neither PHQ-
2 item
Anxiety   
GAD-7 
questionnaire 
Probable Generalised 
Anxiety Disorder 
GAD-7: 10-21 
 
(Severity of GAD: Severe GAD: GAD-7≥15†) 
 Some symptoms of anxiety GAD-7: 5-9
 Anxiety screen negative GAD-7: <5
    
  * Suicidal ideation was defined as a score of “2” or “3” on item 9 of the PHQ-9. 
†In probable GAD, only 1 category of symptom severity exists (severe) as shown. 
 
 
 
Table 2. Descriptive statistics of demographics and disease-related 
variables.  
   N % M SD
Total Number 607   
Female Gender 211 34.8  
Age (years)   47.0 13.9
Ethnicity White British 422 69.5  
 White Other 47 7.7  
 Asian 90 14.8  
 Black 12 2.0  
 Mixed 6 1.0  
 Other 9 1.5  
 Unknown 21 3.5  
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Psoriasis 
Phenotype 
Chronic Plaque 581 95.7  
 Generalised Pustular 8 1.3  
 Localised Pustular 11 1.8  
 Non-pustular Acral 7 1.2  
Treatment Biologics 341 56.2  
 Systemic 154 25.4  
 Phototherapy 4 0.7  
 Topical 74 12.2  
 None 34 5.6  
Psoriatic Arthritis No 146 24.1  
 Yes 109 18.0  
 Unknown 352 58.0  
Previous 
Depression 
No 553 91.1  
 Yes 49 8.1  
 Unknown 5 0.8  
Previous Anxiety No 588 96.9  
 Yes 14 2.3  
 Unknown 5 0.8  
PASI    5.5 5.7
DLQI  3.6 7.1
 
N= number of patients; %= percentage of patient group; M= mean; SD= standard deviation; 
PASI= psoriasis area severity index; DLQI= dermatology life quality index. 
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Table 3.  Demographic and disease variables associated with presence of anxiety and depression in psoriasis patients 
  
Anxiety Depression
    
N(%) OR 95%CI p N(%) OR 95%CI p
Total  79 (13.1)     60 (9.9)    
PASI (0-50)  - 1.07 1.02-0.12 0.007  - 1.10 1.05-1.15 <0.001
Age (8-86)  - 1.00 0.97-1.02 0.69  - 0.99 0.97-1.01 0.46 
Gender Male 44 (55.7) - - -  33 (55.0) - - - 
 Female 35 (44.3) 1.88 1.03-3.42 0.04  27 (45.0) 2.07 1.08-3.97 0.03 
Ethnicity White British 45 (57.0) - - -  36 (60.0) - - - 
 White Other 9 (11.4) 1.82 0.69-4.81 0.23  6 (10.0) 1.06 0.35-3.26 0.92 
 Asian 19 (24.1) 3.42 1.63-7.20 0.001  12 (20.0) 1.96 0.85-4.53 0.12 
 Black 1 (1.3) 1.49 0.17-12.97 0.72  1 (1.7) 1.48 
0.17-
12.88 0.72 
 Mixed 1 (1.3) 1.19 0.11-12.88 0.89  1 (1.7) 1.78 
0.17-
19.15 0.63 
 Other  2 (2.5) 1.66 0.23-12.04 0.62  2 (3.3) 1.38 0.19-9.10 0.75 
 Unknown 2 (2.5) 0.48 0.09-2.49 0.38  2 (3.3) 0.56 0.11-3.00 0.50 
Psoriasis Phenotype Chronic Plaque 74 (93.7) - - -  57 (95.0) - - - 
 
Generalised 
Pustular 1 (1.3) 1.72 0.19-15.91 0.63  1 (1.7) 2.10 
0.23-
18.98 0.51 
 Localised Pustular 3 (3.8) 3.20 0.30-33.80 0.13  1 (1.7) 0.24 
0.00-
28.58 0.56 
 Non-pustular Acral  1 (1.3) 1.13 0.31-4.15 0.86  1 (1.7) 4.98 
0.39-
63.60 0.22 
Treatment Biologics 35 (44.3) - - -  31 (51.7) - - - 
 Systemic 13 (16.5) 0.86 0.38-1.90 0.70  9 (15.0) 0.59 0.24-1.42 0.24 
 Phototherapy 1 (1.3) 7.03 0.58-85.2 0.13  0 (0.0) - - - 
 Topical 26 (32.9) 3.66 1.65-8.10 0.001  16 (26.7) 1.51 0.64-3.58 0.34 
 None 4 (5.1) 1.13 0.31-4.15 0.86  4 (6.7) 0.90 0.24-3.33 0.87 
Psoriatic Arthritis$ No 7 (8.9) - - -  4 (6.7) - - - 
 Yes 14 (17.7) 1.92 1.24-2.98 0.003  12 (20.0) 2.11 1.29-3.45 0.003 
Previous Depression or No 55 (69.6) - - -  41 (68.3) - - - 
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N; number of patients, OR; odds ratio, 95%CI; 95% confidence interval, p; significance level, PASI; psoriasis area severity index, DLQI; 
dermatology life quality index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anxiety 
  Yes 24 (30.4) 8.70 4.14-18.27 <0.001  19 (31.7) 6.86 
3.24-
14.56 <0.001
$ This information was unknown for 44/60 patients (73.3%).  Significant results are shown in bold. 
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